The pharmacy benefits landscape is changing for large employer groups and affecting all parties in the drug supply chain. Recent federal actions, such as the Federal Trade Commission’s investigation into Pharmacy Benefit Managers (“PBMs”)... Read More
Shakespeare’s Hamlet uttered “to be or not to be, that is the question”. Well, large employer groups face a new question, “to sue or not to sue”. Perhaps a little dramatic, but in the rapidly evolving landscape of healthcare and drug... Read More
On May 23, 2023, Blue Cross Blue Shield of Michigan (“BCBSM”) filed a lawsuit against its former Pharmacy Benefits Manager (“PBM”), Express Scripts, Inc. (“ESI”) in the Eastern District of Michigan to recover thousands of dollars in... Read More
In a significant development that could impact the future of prescription drug costs, the U.S. Federal Trade Commission (“FTC”) announced an expansion of its investigation into the country’s leading Pharmacy Benefit Managers (“PBMs”). ... Read More
Frier Levitt Life Sciences attorneys, Dae Y. Lee, Pharm.D., Esq., CPBS and Jonathan Levitt, Esq. co-authored an article titled: “The Consolidated Appropriations Act and PBM Transparency” in Pharmaceutical Executive on May 12, 2023. In this... Read More
Florida-based pharmacies and pharmacists have reason to rejoice following the signing of historic pharmacy benefit manager (“PBM”) legislation into law in Florida. Specifically, on May 3, 2023, Governor DeSantis approved Senate Bill 1550 (“SB... Read More
As discussed in our recent article, the Consolidated Appropriations Act of 2021 (the “CAA”) levels the playing field between pharmacy benefit managers (“PBMs”) and their employee healthcare benefit plan clients (“Plans”) by creating new... Read More
Congress has recently increased its scrutiny of Pharmacy Benefit Managers (“PBMs”), coinciding with a crucial policy shift by the Federal Trade Commission (“FTC”) that appears promising for independent pharmacies and other providers seeking... Read More
Earlier this month, House Representative Earl L. (“Buddy”) Carter (R-GA) introduced the Drug Price Transparency in Medicaid Act of 2023 (H.R. 1613) (the “Act”) in an effort to improve transparency and curb abusive practices related to the... Read More
PRESS RELEASE – New Jersey/New York, March 28, 2023 – Jonathan Levitt, a renowned trial attorney in the healthcare and life sciences industries and the co-founding partner of Frier Levitt, has been invited to testify before the U.S. Senate... Read More
